Company Analysis
Sign in

Tonix Pharmaceuticals Holding Corp. (TNXP)

Nasdaq: TNXP · Pharmaceutical Preparations · Berkeley Heights, NJ · filing with the SEC since 2008
Full chart Alerts Compare
Grade4.6
◀ Past 3.4● Present 5.3▶ Future 4.6
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Tonix Pharmaceuticals Holding Corp.

Nine metrics read from its own filings, by tense
Headline grade
4.6/10
◀ Past3.425% of the headline
● Present5.335% of the headline
▶ Future4.640% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.4/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.1/10

Has it survived what it has been through?

14 warning events since 2017; the latest 2026-03-18.

weight 22% of this tense · 11th percentile among 497 sector filers · read for itself

From the record

Tonix Pharmaceuticals Holding Corp.'s filings since 2017 show 14 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 11 times, the latest 2024-08-09); an auditor change (8-K item 4.01, the latest 2026-03-18); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2024-08-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
7.0/10

What has it actually done, year after year?

+29.9% a year over 3 filed years; profitable in 0 of 3.

weight 45% of this tense · 69th percentile among 323 sector filers · read for its customers

From the record

Tonix Pharmaceuticals Holding Corp.'s 3 filed years say what it did: revenue went from $8 million in fiscal 2023 to $13 million in fiscal 2025, up 29.9% a year; it rose in 2 of 2 years; it never fell from a peak; net income was positive in 0 of 3 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span29.9%top 31% of its family
  • the share of years revenue rosetop 8% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
0.2/10

How has it treated the people who own it?

SI estimate 0.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 2nd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 2% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Tonix Pharmaceuticals Holding Corp.'s shareholder treatment is put at 0.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 2% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.3/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
3.9/10

Is it financially healthy right now?

ROE -51%: lost 51¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar.

weight 45% of this tense · 39th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Tonix Pharmaceuticals Holding Corp. lost about 51 cents for every dollar of shareholders' money, and gross profitability: its products earned about 2 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 12 cents per dollar of assets, and net share issuance: its share count grew 1055.9% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 19% of its family
  • return on equitytop 50% of its family
  • gross profit against assetsbottom 19% of its family
  • the share count against the year beforebottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
4.8/10

How strong is its position in its industry?

bottom 48% of 315 in its family; net margin -946.2%.

weight 22% of this tense · 48th percentile among 315 sector filers · read for its customers

From the record

Tonix Pharmaceuticals Holding Corp.'s standing among 315 graded names in its industry family: revenue of $13 million in fiscal 2025 ranks in the bottom 45% by size; a net margin of -946.2% ranks in the bottom 31%; revenue growth of 29.9% a year over the last 2 filed years ranks in the top 31% (its annual reports).

What it rests on

  • revenue against the family$13.1Mbottom 45% of its family
  • net margin-946.2%bottom 31% of its family
  • three-year revenue growth29.9%top 31% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
7.6/10

What are the people in charge doing?

top 24% of 315 in its family for leadership; chief executive since 2013.

weight 33% of this tense · 76th percentile among 315 sector filers · read for its shareholders

From the record

Tonix Pharmaceuticals Holding Corp.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lederman, Seth (Chief Executive Officer, as filed), filing under that title since 2013-01-14, 13.8 years (top 7% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 8 years (top 20%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 45%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge6 in three years among 14 peopletop 45% of its family
  • the median years the people in charge have filed8.0 yearstop 20% of its family
  • the chief executive's years on the record13.8 yearstop 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.6/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed
4.9/10

How much room does it have to grow?

bottom 49% of 273 in its family for room to expand.

weight 33% of this tense · 49th percentile among 273 sector filers · read for itself

From the record

Tonix Pharmaceuticals Holding Corp.'s room to grow, from the newest filed statements (fiscal 2025): cash of $208 million against no long-term debt tagged leaves 74.9% of its assets as net cash, top 21% of its family; cash from operations less capital spending is -787.5% of revenue (bottom 28%); a gross margin of 49.3% (bottom 25%); research spending of 339.4% of revenue (top 36%) (its annual report).

What it rests on

  • cash less debt against assets74.9%top 21% of its family
  • cash from operations less capital spending against revenue-787.5%bottom 28% of its family
  • gross margin49.3%bottom 25% of its family
  • research spending against revenue339.4%top 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
4.0/10

What could actually drive growth from here?

bottom 41% of 306 in its family for growth drivers.

weight 45% of this tense · 41st percentile among 306 sector filers · read for its customers

From the record

Tonix Pharmaceuticals Holding Corp.'s growth drivers, from the filed years to fiscal 2025: revenue grew 29.9% a year over the last three filed years against 29.9% over all 3, speeding up (top 40% of its family); the newest year grew 29.9% (top 32%); research spending grew -18.4% a year (bottom 19%); capital spending grew -58.8% a year (bottom 14%) (its annual reports). Tonix Pharmaceuticals Holding Corp. reported 3 product lines in fiscal 2025: Zembrace Symtouch at $9 million (71%), Tosymra at $2 million (18%), Tonmya at $1 million (11%); 2 of 2 grew against the year before (its annual report).

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 40% of its family
  • the newest year's revenue growth29.9%top 32% of its family
  • three-year growth of research spending-18.4%bottom 19% of its family
  • three-year growth of capital spending-58.8%bottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
family median, 234 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Tonix Pharmaceuticals Holding Corp.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton TNXP · research, not advice